抗T淋巴细胞球蛋白对HLA相合无关供者清髓性造血细胞移植患者无慢性移植物抗宿主病生存影响的前瞻性随机双盲III期临床试验
这项前瞻性随机双盲III期试验纳入254例接受HLA相合无关供者清髓性造血细胞移植的急性白血病或骨髓增生异常综合征患者,1:1随机接受安慰剂(n=128)或ATLG(n=126)治疗。ATLG组2-4级急性GVHD(23% vs 40%,P=.004)和中重度慢性GVHD(12% vs 33%,P<.001)均降低,但中重度慢性GVHD无病生存无差异(2年估计值48% vs 44%,P=.47),且无进展生存(47% vs 65%,P=.04)和总生存(59% vs 74%,P=.034)更低。
要点
- ATLG组2-4级急性GVHD为23%,安慰剂组为40%(P=.004)。
- ATLG组中重度慢性GVHD为12%,安慰剂组为33%(P<.001)。
- 中重度慢性GVHD无病生存2年估计值ATLG组48% vs 安慰剂组44%(P=.47)。
核心结论
- 在无关供者清髓性造血细胞移植中,加入ATLG未改善中重度慢性GVHD无病生存。
- ATLG组中重度慢性GVHD显著降低,但无进展生存和总生存也降低。
- 需要额外分析以理解ATLG在造血细胞移植中的合适作用。
研究设计与样本
- 前瞻性、随机、双盲III期临床试验,在27个中心进行。
- 纳入254例18至65岁急性白血病或骨髓增生异常综合征患者,接受清髓性HLA相合无关供者造血细胞移植。
- 患者1:1随机接受安慰剂(n=128)或ATLG(n=126)。
- ATLG或安慰剂20 mg/kg/天,于-3、-2、-1天给药,联合他克莫司和甲氨蝶呤作为GVHD预防。
- 主要研究终点为中重度慢性GVHD无病生存。
主要发现
- ATLG组2-4级急性GVHD为23%,安慰剂组为40%(P=.004)。
- ATLG组中重度慢性GVHD为12%,安慰剂组为33%(P<.001)。
- 中重度慢性GVHD无病生存2年估计值ATLG组48% vs 安慰剂组44%(P=.47)。
- 无进展生存2年估计值ATLG组47% vs 安慰剂组65%(P=.04)。
- 总生存2年估计值ATLG组59% vs 安慰剂组74%(P=.034)。
关键数值与推荐
- 多变量分析证实ATLG与较差的无进展生存相关(风险比1.55;95%CI 1.05至2.28;P=.026)。
- 多变量分析证实ATLG与较差的总生存相关(风险比1.74;95%CI 1.12至2.71;P=.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Several open-label randomized studies have suggested that in vivo T-cell depletion with anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising survival. We report a prospective, double-blind phase III trial to investigate the effect of ATLG (Neovii Biotech, Lexington, MA) on cGVHD-free survival. Patients and Methods Two hundred fifty-four patients 18 to 65 years of age with acute leukemia or myelodysplastic syndrome who underwent myeloablative HLA-matched unrelated hematopoietic cell transplantation (HCT) were randomly assigned one to one to placebo (n =128 placebo) or ATLG (n = 126) treatment at 27 sites. Patients received either ATLG or placebo 20 mg/kg per day on days -3, -2, -1 in addition to tacrolimus and methotrexate as GVHD prophylaxis. The primary study end point was moderate-severe cGVHD-free survival. Results Despite a reduction in grade 2 to 4 acute GVHD (23% v 40%; P = .004) and moderate-severe cGVHD (12% v 33%; P < .001) in ATLG recipients, no difference in moderate-severe cGVHD-free survival between ATLG and placebo was found (2-year estimate: 48% v 44%, respectively; P = .47). Both progression-free survival (PFS) and overall survival (OS) were lower with ATLG (2-year estimate: 47% v 65% [ P = .04] and 59% v 74% [ P = .034], respectively). Multivariable analysis confirmed that ATLG was associated with inferior PFS (hazard ratio, 1.55; 95% CI, 1.05 to 2.28; P = .026) and OS (hazard ratio, 1.74; 95% CI, 1.12 to 2.71; P = .01). Conclusion In this prospective, randomized, double-blind trial of ATLG in unrelated myeloablative HCT, the incorporation of ATLG did not improve moderate-severe cGVHD-free survival. Moderate-severe cGVHD was significantly lower with ATLG, but PFS and OS also were lower. Additional analyses are needed to understand the appropriate role for ATLG in HCT.
引用
- Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol. 2017. PMID: 29040031. doi:10.1200/JCO.2017.75.8177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。